Skip to main content
Smart Investors Daily
Interpace Biosciences, Inc. logo

OTC · IDXG

Interpace Biosciences, Inc.

Healthcare · Medical - Diagnostics & Research

$6.51

Down-$0.47 (-6.73%)

Updated Sep 17, 2026, 10:12 AM

SID Score

3.7/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
6.63M
P/E ratio
1.28
Dividend yield
0.00%
52-week range
— – —
Volume
4.2K
Avg. volume
9.11K

Price performance

IDXG price history

1M range · 0 trading sessions · Daily adjusted prices

IDXG does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IDXG news

The latest Smart Investors Daily articles mentioning IDXG.

IDXG research

Overview

Company profile and research snapshot.

Company profile

INTERPACE BIOSCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
IDXG recent ratings
DateFirmRatingTarget
Nov 17, 2021HC Wainwright & Co.Neutral
Apr 9, 2021HC Wainwright & Co.Buy
Jan 25, 2021HC Wainwright & Co.Buy
Oct 22, 2020HC Wainwright & Co.Buy
Jun 26, 2020HC Wainwright & Co.Buy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Dec 3, 2025

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners

PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021, with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.